Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis reported Q2 financial results with cash, cash equivalents, and short-term investments of $282.3 million, extending the company's cash runway into the second half of 2029. The company announced positive FDA pre-IND feedback for Privosegtor in acute MS relapses, eliminating the need for additional preclinical studies and supporting an IND submission in Q4 2026, while the PREDICT-1 trial for Licaminlimab is over 45% enrolled.
Key figures
- Cash runway
- 2H 2029
- Net loss 6m
- $49.3 million
- Cash position
- $282.3 million
- Ga expenses q2
- $10.9 million
- Rd expenses q2
- $19.3 million
- Licaminlimab enrollment
- >45%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.